Circulation Research. 2004;95:233-238
doi: 10.1161/01.RES.0000137876.28454.64
doi: 10.1161/01.RES.0000137876.28454.64
© 2004 American Heart Association, Inc.
Reviews |
Protein Glycation
A Firm Link to Endothelial Cell Dysfunction
From the University Lariboisiere-Saint Louis and Institut National de la Transfusion Sanguine (J.-L.W.), Paris, France; and Columbia University (A.M.S.), College of Physicians & Surgeons, New York, NY.
Correspondence to Jean-Luc Wautier, MD, PhD, University Lariboisiere-Saint Louis, Paris 7, INTS, Vascular and cellular biology Laboratory, 6 rue Alexandre Cabanel, 75739 Paris cedex 15, France. E-mail jlwautier{at}ints.fr
This Review is part of a thematic series on Cardiovascular Role of Sugar Modifications, which includes the following articles:
Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond
Protein Glycation: A Firm Link to Endothelial Cell Dysfunction
David A. Kass Editor
The advanced glycation end products (AGEs) are a heterogeneous class of molecules, including the following main subgroups: bis(lysyl)imidazolium cross-links, hydroimidazolones, 3-deoxyglucosone derivatives, and monolysyl adducts. AGEs are increased in diabetes, renal failure, and aging. Microvascular lesions correlate with the accumulation of AGEs, as demonstrated in diabetic retinopathy or renal glomerulosclerosis. On endothelial cells, ligation of receptor for AGE (RAGE) by AGEs induces the expression of cell adhesion molecules, tissue factor, cytokines such as interleukin-6, and monocyte chemoattractant protein-1. A chief means by which AGEs via RAGE exert their effects is by generation of reactive oxygen species, at least in part via stimulation of NADPH oxidase. Diabetes-associated vascular dysfunction in vivo can be prevented by blockade of RAGE. Thus, agents that limit AGE formation, increase the catabolism of these species, or antagonize their binding to RAGE may provide new targets for vascular protection in diabetes.
Key Words: glycated proteins • (carboxymethyl)lysine • 3-deoxyglucosone • endothelial cells • vascular permeability • oxidant stress
This article has been cited by other articles:
 |
|
 |
|
  D. S. Wilkes Primary Graft Dysfunction: It's All the RAGE Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 915 - 916. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Christie, C. V. Shah, S. M. Kawut, N. Mangalmurti, D. J. Lederer, J. R. Sonett, V. N. Ahya, S. M. Palmer, K. Wille, V. Lama, et al. Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Baba, O. A. Barski, Y. Ahmed, T. E. O'Toole, D. J. Conklin, A. Bhatnagar, and S. Srivastava Reductive Metabolism of AGE Precursors: A Metabolic Route for Preventing AGE Accumulation in Cardiovascular Tissue Diabetes, November 1, 2009; 58(11): 2486 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, October 1, 2009; 48(10): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Davies, A. L. Herrick, L. Cordingley, A. J. Freemont, and M. Jeziorska Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis Rheumatology, August 1, 2009; 48(8): 876 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ignace, D. Fouque, W. Arkouche, J.-P. Steghens, and F. Guebre-Egziabher Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1685 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Siekmeier, T. Grammer, and W. Marz Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 279 - 297. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197. [Abstract] [PDF]
|
|
|
|
|
|
A. Soro-Paavonen, A. M.D. Watson, J. Li, K. Paavonen, A. Koitka, A. C. Calkin, D. Barit, M. T. Coughlan, B. G. Drew, G. I. Lancaster, et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes Diabetes, September 1, 2008; 57(9): 2461 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Omori, T. Ohira, Y. Uchida, S. Ayilavarapu, E. L. Batista Jr., M. Yagi, T. Iwata, H. Liu, H. Hasturk, A. Kantarci, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase J. Leukoc. Biol., July 1, 2008; 84(1): 292 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Talmor, E. Golan, S. Benchetrit, J. Bernheim, O. Klein, J. Green, and G. Rashid Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1059 - F1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boodhwani, N. R. Sodha, S. Mieno, B. Ramlawi, S.-H. Xu, J. Feng, R. T. Clements, M. Ruel, and F. W. Sellke Insulin treatment enhances the myocardial angiogenic response in diabetes. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1453 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Rao, K. J. Tracey, and J. S. Pober IL-1{alpha} and IL-1beta Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response J. Immunol., November 15, 2007; 179(10): 6536 - 6546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gundewar, J. W. Calvert, J. W. Elrod, and D. J. Lefer Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2462 - H2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Navaratna, P. G. McGuire, G. Menicucci, and A. Das Proteolytic Degradation of VE-Cadherin Alters the Blood-Retinal Barrier in Diabetes Diabetes, September 1, 2007; 56(9): 2380 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mallidis, I. Agbaje, D. Rogers, J. Glenn, S. McCullough, A. B. Atkinson, K. Steger, A. Stitt, and N. McClure Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus Hum. Reprod., August 1, 2007; 22(8): 2169 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Stakos, D. P Schuster, E. A Sparks, S. B. Meis, C. F Wooley, K. Osei, and H. Boudoulas Association between glycosylated hemoglobin, left ventricular mass and aortic function in nondiabetic individuals with insulin resistance Eur. J. Endocrinol., July 1, 2007; 157(1): 63 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Han, A. E. Woytowich, A. K. Mandal, and L. M. Hiebert Heparanase Upregulation in High Glucose-Treated Endothelial Cells Is Prevented by Insulin and Heparin Experimental Biology and Medicine, July 1, 2007; 232(7): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Galli Protein damage and inflammation in uraemia and dialysis patients Nephrol. Dial. Transplant., July 1, 2007; 22(suppl_5): v20 - v36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Atkins and M. K. Jain Role of Kruppel-Like Transcription Factors in Endothelial Biology Circ. Res., June 22, 2007; 100(12): 1686 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marsche, M. Semlitsch, A. Hammer, S. Frank, B. Weigle, N. Demling, K. Schmidt, W. Windischhofer, G. Waeg, W. Sattler, et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway FASEB J, April 1, 2007; 21(4): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Facchiano, D. D'Arcangelo, K. Russo, V. Fogliano, C. Mennella, R. Ragone, G. Zambruno, V. Carbone, D. Ribatti, C. Peschle, et al. Glycated Fibroblast Growth Factor-2 Is Quickly Produced in Vitro upon Low-Millimolar Glucose Treatment and Detected in Vivo in Diabetic Mice Mol. Endocrinol., November 1, 2006; 20(11): 2806 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Zhao, S. Wang, H. Cheng, M.-z. Zhang, T. Takahashi, A. B. Fogo, M. D. Breyer, and R. C. Harris Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic Mice J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]
|
|
|
|
|
|
C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes, May 1, 2006; 55(5): 1478 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stam, C. G. Schalkwijk, C. van Guldener, P. M. ter Wee, and C. D. A. Stehouwer Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals Nephrol. Dial. Transplant., March 1, 2006; 21(3): 677 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Katakami, M. Matsuhisa, H. Kaneto, and Y. Yamasaki Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. Diabetes Care, February 1, 2006; 29(2): 469 - 469. [Full Text] [PDF]
|
|
|
|
|
|
N. Katakami, M. Matsuhisa, H. Kaneto, T.-a. Matsuoka, K. Sakamoto, Y. Nakatani, K. Ohtoshi, R. Hayaishi-Okano, K. Kosugi, M. Hori, et al. Decreased Endogenous Secretory Advanced Glycation End Product Receptor in Type 1 Diabetic Patients: Its possible association with diabetic vascular complications Diabetes Care, November 1, 2005; 28(11): 2716 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Southerland, G. W. Taylor, and S. Offenbacher Diabetes and Periodontal Infection: Making the Connection Clin. Diabetes, October 1, 2005; 23(4): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Najjar, A. Scuteri, and E. G. Lakatta Arterial Aging: Is It an Immutable Cardiovascular Risk Factor? Hypertension, September 1, 2005; 46(3): 454 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Cacicedo, S. Benjachareowong, E. Chou, N. B. Ruderman, and Y. Ido Palmitate-Induced Apoptosis in Cultured Bovine Retinal Pericytes: Roles of NAD(P)H Oxidase, Oxidant Stress, and Ceramide Diabetes, June 1, 2005; 54(6): 1838 - 1845. [Abstract] [Full Text] [PDF]
|
|